Hennion & Walsh Asset Management Inc. Makes New $1.74 Million Investment in Fulgent Genetics, Inc. $FLGT
Hennion & Walsh Asset Management Inc. has made a new investment of $1.74 million in Fulgent Genetics, acquiring 66,190 shares representing 0.21% of the company. Despite beating quarterly EPS estimates, Fulgent Genetics remains unprofitable and analysts maintain a "Hold" rating with an average target price of $32.00. Institutional investors collectively own about 48.06% of the stock.
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is
Bragar Eagel & Squire, P.C. has launched an investigation into Fulgent Genetics, Inc. (NASDAQ:FLGT) following a significant drop in its stock price. The investigation concerns potential violations of federal securities laws after Fulgent Genetics released lower-than-expected 2026 guidance, attributing it to a major customer moving work in-house. Investors who suffered losses are encouraged to contact the law firm to discuss their legal rights.
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) following a significant 38.1% drop in share price. This decline occurred after Fulgent issued lower-than-expected guidance for 2026, stemming from a major customer moving a substantial portion of its work in-house. The firm encourages investors who suffered losses to contact them to discuss their legal options.
[ARS] Fulgent Genetics, Inc. SEC Filing
This article reports on an ARS SEC filing by Fulgent Genetics, Inc. (FLGT) dated March 31, 2026, noting a low filing impact and neutral sentiment. It provides details about the filing type and acceptance date, along with recent news and other SEC filings related to the company. The article also includes key stock data for Fulgent Genetics.
FLGT PE Ratio & Valuation, Is FLGT Overvalued
Fulgent Genetics Inc (FLGT) is currently considered undervalued, with a forward PS ratio of 1.25 compared to its five-year average. Its fair price is estimated between $20.37 and $43.53, making the current price of $15.90 undervalued by 21.93%. The article also examines FLGT's P/B ratio, FCF yield, and P/S ratio in comparison to industry averages and historical data.
JPMorgan Chase & Co. Increases Position in Fulgent Genetics, Inc. $FLGT
JPMorgan Chase & Co. significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 767.0% in the third quarter, now owning 299,014 shares worth $6.76 million. Other institutional investors have also adjusted their positions in the company, which recently reported earnings of $0.16 per share, beating consensus estimates. Analysts currently have a "Hold" rating on FLGT with an average target price of $32.00.
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc
Kirby McInerney LLP is investigating potential federal securities law violations by Fulgent Genetics Inc. (NASDAQ: FLGT) and its management following a significant drop in its stock price. The decline occurred on February 27, 2026, after Fulgent issued lower-than-expected 2026 guidance, attributing it to a major customer moving work in-house. The law firm is encouraging investors who purchased Fulgent securities to contact them to discuss their legal rights.
Fulgent Genetics (NASDAQ: FLGT) CEO cancels 750,000-share prepaid forward
Fulgent Genetics CEO Ming Hsieh, through The Ming Hsieh Trust, canceled a prepaid variable forward arrangement involving 750,000 shares of common stock. The trust paid an aggregate of $10,708,875 to an unaffiliated bank to unwound the agreement, releasing the shares from being pledged. This transaction, detailed in a Form 4/A filing, indicates a notable change in Hsieh's indirect holdings as the shares are now fully unencumbered and remain with the trust.
Fulgent Genetics (NASDAQ: FLGT) CEO reports 30.7% ownership stake
Ming Hsieh, CEO of Fulgent Genetics (NASDAQ: FLGT), now beneficially owns 30.74% of the company's common stock, totaling 8,867,303 shares as of March 27, 2026. This updated ownership includes shares held through The Ming Hsieh Trust and reflects changes primarily due to the vesting of restricted stock units (RSUs) and performance-based RSUs, with some shares sold or withheld for tax obligations. The filing also notes the termination of two pre-paid forward arrangements and details shares pledged as collateral for a credit facility.
Fulgent Genetics (FLGT) price target decreased by 27.72% to 24.82
This article reports a significant decrease in the price target for Fulgent Genetics (FLGT), with analysts lowering it by 27.72% to $24.82. The content is very brief, indicating that this is likely an automated update or a preliminary notification of an analyst rating change.
Technical Reactions to FLGT Trends in Macro Strategies
The article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT) using AI models, indicating strong sentiment across all horizons for an overweight bias despite a current breakdown. It provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis suggests elevated downside risk due to the lack of additional long-term support signals.
Short Interest in Fulgent Genetics, Inc. (NASDAQ:FLGT) Rises By 38.7%
Short interest in Fulgent Genetics, Inc. (NASDAQ:FLGT) significantly increased by 38.7% in March, reaching 2,135,898 shares, which represents 10.2% of the stock. Shares traded down approximately 4.8% to $15.59, and the company has received mixed analyst ratings, with a consensus "Hold" but several downgrades and a target price of $32.00. Institutional investors have made various adjustments to their holdings in the stock, with 48.06% of the company's stock owned by institutional investors and hedge funds.
Short Interest in Fulgent Genetics Rises 38.7%
Short interest in Fulgent Genetics (NASDAQ:FLGT) increased by 38.7% in March, indicating growing skepticism among investors regarding the biotech firm's future. This surge in short selling comes as the company's stock price has declined, missing analyst expectations amidst increased competition in the genetic testing market. Investors are closely watching upcoming earnings reports and competitive positioning to gauge the company's long-term prospects.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Rating of "Hold" from Brokerages
Fulgent Genetics (NASDAQ:FLGT) has received a consensus "Hold" rating from brokerages, with an average one-year price target of $32.00. Recent analyst downgrades from firms like Zacks and Wall Street Zen have contributed to this outlook, despite the company beating EPS estimates in its latest quarter. The stock opened at $15.59 and trades below its 50-day and 200-day moving averages, with a current market capitalization of $486.89 million.
Fulgent Genetics (FLGT) price target decreased by 27.72% to 24.82
The price target for Fulgent Genetics (FLGT) has been decreased by 27.72%, bringing it down to $24.82. This adjustment reflects a significant re-evaluation of the company's valuation.
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (NASDAQ:FLGT) and its management following a significant drop in share price. The investigation stems from Fulgent's lower-than-expected 2026 guidance, announced on February 27, 2026, which led to a 38.1% decline in the stock after its largest customer moved work in-house. Investors affected by the share price drop are encouraged to contact the law firm to learn more about their rights.
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
Kirby McInerney LLP is investigating potential federal securities law violations and unlawful business practices by Fulgent Genetics Inc. following a significant drop in share price. This decline occurred after Fulgent provided lower-than-expected guidance for 2026, attributing it to a major customer moving work in-house. The law firm is currently seeking information from investors who purchased Fulgent securities to determine if a lawsuit can be filed.
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
Kirby McInerney LLP is investigating potential claims against Fulgent Genetics Inc. (NASDAQ: FLGT) on behalf of investors. This investigation follows a significant 38.1% drop in Fulgent's share price after the company released lower-than-expected 2026 guidance, attributing it to a major customer moving work in-house. Investors who purchased Fulgent securities are encouraged to contact the firm regarding their rights.
If You Invested $1,000 in Fulgent Genetics (FLGT)
This article analyzes the historical performance of a $1,000 investment in Fulgent Genetics (FLGT) over one, five, and ten years, comparing its returns to the S&P 500. It details the company's business model, encompassing laboratory services and therapeutic development with a focus on oncology, and highlights its strategic shift towards becoming a fully integrated precision medicine company through technological advancements and acquisitions. The report also provides key financial metrics and an overview of FLGT's market position.
Fulgent Genetics completes $56.9M pathology lab acquisitions
Fulgent Genetics (NASDAQ:FLGT) has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million in cash. This strategic move expands Fulgent's laboratory services in anatomic pathology, molecular genetic testing, and dermatopathology. Despite a year-to-date stock decline, the company's valuation is considered undervalued, and it maintains a strong liquidity position, although recent revenue reports indicate challenges with customer volume.
Fulgent Genetics Completes $56.9M Acquisition of Bako Diagnostics and StrataDx to Expand Precision Medicine Services
Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million in cash. This strategic move aims to expand Fulgent's presence in pathology and dermatopathology laboratory services, furthering its transition into a fully integrated precision medicine company. The acquisitions are expected to diversify revenue, enhance service offerings, and strengthen Fulgent's position in the specialty testing markets.
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics announced the completion of its acquisition of Bako Diagnostics and StrataDx for a total combined purchase price of approximately $56.9 million in cash. This strategic move aims to transform Fulgent from a diagnostic business into a fully integrated precision medicine company. The transaction was advised by Piper Sandler & Co. and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. for Fulgent, and EV Health Partners and Latham & Watkins LLP for Consonance Capital Partners, Bako Diagnostics, and StrataDx.
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics has announced the completion of its acquisition of Bako Diagnostics and StrataDx for a total combined purchase price of approximately $56.9 million in cash. Bako Diagnostics is a premier national provider of specialty laboratory testing services, while StrataDx is a national diagnostic laboratory specializing in dermatopathology. This acquisition aims to support Fulgent's transformation from a diagnostics business into a fully integrated precision medicine company.
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has launched an investigation into potential securities fraud claims against Fulgent Genetics Inc. (NASDAQ:FLGT). This follows Fulgent's announcement of lower-than-expected 2026 guidance, attributed to a major customer moving work in-house, which caused a significant 38.1% drop in the company's stock price. The law firm encourages affected investors to contact them to discuss their legal rights regarding this matter.
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics has announced the completion of its acquisition of Bako Diagnostics and StrataDx for approximately $37.9 million in cash. This strategic move aims to expand Fulgent's laboratory services business and transform it into a fully integrated precision medicine company. The acquisition includes premier pathology and dermatopathology laboratories, enhancing Fulgent's diagnostic and therapeutic development capabilities.
Fulgent Genetics (NASDAQ: FLGT) buys Bako Diagnostics and StrataDx
Fulgent Genetics, through its subsidiary Inform Diagnostics, has completed the acquisitions of dermatopathology lab StrataDx for $13.5 million and substantially all assets of Bako Diagnostics for $43.4 million, totaling approximately $56.9 million in cash. These actions expand Fulgent's pathology footprint and bring national dermatopathology and podiatric pathology capabilities under its umbrella. The company also assumed a long-term lease for lab and office space in Alpharetta, Georgia, as part of the Bako transaction.
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics (NASDAQ: FLGT) has announced the completion of its acquisition of Bako Diagnostics and StrataDx, two pathology laboratories, for approximately $56.9 million in cash. This acquisition, previously announced on December 22, 2025, aims to transform Fulgent from a diagnostic business into a fully integrated precision medicine company. The company's goal is to expand its laboratory services and therapeutic development business while developing drug candidates for cancer treatment.
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has announced an investigation into potential securities fraud against Fulgent Genetics Inc. (NASDAQ: FLGT). This follows a significant drop in Fulgent's share price on February 27, 2026, after the company provided lower-than-expected guidance for 2026, attributing it to a major customer moving work in-house. The law firm is encouraging investors who purchased Fulgent securities to contact them regarding their rights.
Fulgent Genetics (NASDAQ:FLGT) Stock Price Crosses Below 50-Day Moving Average - Here's Why
Shares of Fulgent Genetics (NASDAQ:FLGT) have fallen below their 50-day moving average, trading as low as $14.79. The company has a current market cap of $466.90 million and recently reported Q4 earnings of $0.16 EPS, exceeding analyst estimates, but revenue missed expectations. Several analysts have adjusted their ratings on FLGT, leading to a consensus "Hold" rating with an average price target of $32.00.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's announcement of its fourth-quarter and full-year 2025 financial results, which showed that full-year revenue of approximately $322.7 million fell slightly short of updated guidance and fourth-quarter revenue declined sequentially. Investors who experienced losses in Fulgent securities are encouraged to contact the firm for more information.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg, P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported full-year 2025 revenue that fell short of guidance and a sequential decline in fourth-quarter revenue. The firm is encouraging investors who suffered losses to contact their attorneys to discuss participation in the investigation. Lowey Dannenberg is a national law firm specializing in representing investors harmed by corporate fraud.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics
Lowey Dannenberg, P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported fourth-quarter revenue decline and full-year 2025 revenue that fell short of guidance. Investors who suffered losses are encouraged to contact the firm to learn more about the investigation.
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential securities fraud and may file a class action lawsuit. This comes after Fulgent's stock price dropped significantly by 38.09% following its Q4 and full-year 2025 financial results. The decline was attributed to lower-than-expected 2026 guidance, as the company's largest customer moved a substantial portion of its work in-house, impacting revenue and growth projections.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg, P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's report of fourth-quarter 2025 revenue decline and full-year revenue that fell short of updated guidance. Investors who suffered losses are encouraged to contact the firm.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws after the company reported lower-than-expected full-year 2025 revenue and a decline in fourth-quarter revenue. Investors who suffered losses in the company's securities are encouraged to contact the firm to discuss participating in the investigation. Lowey Dannenberg is a national firm specializing in representing investors in cases of corporate fraud.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics
Lowey Dannenberg, P.C. is investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's report of fourth-quarter revenue decline and full-year 2025 revenue falling slightly short of updated guidance. The firm encourages investors who suffered losses in Fulgent securities to contact them regarding the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Pomerantz LLP has announced an investigation into Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows a significant drop in Fulgent's stock price by 38.09% on February 27, 2026, after the company provided lower-than-expected guidance for 2026, citing its largest customer moving work in-house. Investors are advised to contact Danielle Peyton for more information about potentially joining a class action.
Fulgent Genetics (NASDAQ: FLGT) CEO pays $10.7M to cancel share forward
Fulgent Genetics (NASDAQ: FLGT) CEO Ming Hsieh, through his trust, paid $10.7 million to cancel a prepaid variable forward contract on 750,000 shares. This action removes the pledge on these shares, which were originally part of an agreement made in 2023, without altering his direct or indirect substantial equity holdings in the company. The transaction is a restructuring of financing, not an open-market trade, and maintains Hsieh's economic exposure to FLGT shares.
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from "hold" to "sell," leading to a split among analysts with a consensus "Hold" rating and a $32 target price. The company's shares are trading around $14.63, with a market capitalization of approximately $457 million. Although Fulgent Genetics beat quarterly EPS estimates, revenue fell short, and the company reported negative net margin and return on equity, with FY2026 guidance indicating continued weakness and projected negative EPS of -$0.85 for the year.
Fulgent Genetics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:FLGT)
Fulgent Genetics, Inc. (NASDAQ:FLGT) released its Q4 2025 earnings call presentation, reporting an EPS of $0.16, which beat estimates by $0.13. However, the company's revenue of $83.34 million missed expectations by $2.04 million, despite a 9.34% year-over-year increase. The provided slide deck contains details shared during their earnings call.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Pomerantz LLP is investigating potential securities fraud claims against Fulgent Genetics, Inc. (FLGT). The investigation follows a significant drop in Fulgent's stock price after the company reported lower-than-expected 2026 guidance, citing its largest customer moving substantial work in-house. Investors are encouraged to contact Pomerantz LLP for information on joining a potential class action.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Brokerages
Fulgent Genetics, Inc. (NASDAQ:FLGT) has received an average rating of "Hold" from five brokerages. Analysts have provided one sell, two hold, and two buy ratings, with a 1-year average price target of $32.00. The company reported quarterly earnings of $0.16 per share, beating consensus estimates, and reported revenue of $83.34 million against an $85.38 million estimate.
Fulgent Genetics Hits New 52-Week Low at $14.01 Amid Declining Performance
Fulgent Genetics, a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of $14.01. The company has seen its stock price decline by 30.29% over the past year, significantly underperforming the S&P 500, and currently operates at a loss with no dividends. Despite these challenges, institutional holdings remain strong at 63.82%, indicating some investor confidence.
Fulgent Genetics (NASDAQ: FLGT) CEO has shares withheld for taxes
Fulgent Genetics CEO Ming Hsieh reported tax-related share withholdings instead of open-market sales. On March 1, 2026, 17,566 shares were withheld at $15.33 to cover tax obligations from vested restricted stock units, leaving him with 900,634 directly held shares. An earlier withholding on February 26, 2026, involved 2,949 shares at $24.76.
Fulgent Genetics (NASDAQ: FLGT) CFO has shares withheld for RSU taxes
Fulgent Genetics (NASDAQ: FLGT) CFO and Treasurer Paul Kim reported that shares of common stock were withheld to cover tax obligations arising from vested restricted stock units (RSUs) on February 26 and March 1, 2026. These transactions were tax-withholding dispositions, not open-market sales, occurring at prices of $24.76 and $15.33 per share. This indicates the satisfaction of tax liabilities related to RSU vesting rather than a discretionary sale by the insider.
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress
Fulgent Genetics (FLGT) reported 2025 sales of US$322.67 million and expects US$350 million in 2026 revenue, yet its stock declined significantly post-earnings. Despite a valuation narrative suggesting the stock is 54.5% undervalued at $33.67 per share, market ratios indicate a premium for growth that hasn't materialized in profits. Investors are urged to consider both the potential for growth from new clinical recommendations and enhanced sequencing services, alongside ongoing risks like operating losses and high cash needs for early-stage therapies.
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT) following a disclosure that the company's full-year 2025 revenue fell short of guidance and that a major customer transition would impact 2026 revenue. The investigation will focus on whether Fulgent's executive officers complied with federal securities laws after the company's shares declined. Shareholders who suffered losses are encouraged to join the investigation.
UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating
UBS has adjusted its price target for Fulgent Genetics (FLGT) to $22, down from $35, while reiterating a "Buy" rating on the stock. This update follows recent financial news from Fulgent Genetics, including its Q4 2025 earnings call and 2026 guidance, which projected lower revenue and a higher adjusted loss than FactSet estimates. The company's stock has seen significant declines year-to-date, despite a recent acquisition.
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress
Fulgent Genetics (FLGT) has seen significant share price volatility after its latest earnings report, despite a common valuation narrative suggesting it's 54.5% undervalued with a fair value of $33.67. The company reported 2025 sales of US$322.67 million, a wider net loss, and projected 2026 revenue of about US$350 million, benefiting from broader medical society endorsements for genome/exome sequencing. However, ongoing operating losses and early-stage cancer therapies introduce execution risk, with market ratios like P/S suggesting a premium for growth that has not yet translated into profits.
Tax share withholdings for Fulgent Genetics (NASDAQ: FLGT) COO
Fulgent Genetics President and COO Jian Xie reported tax-related share withholdings to cover obligations from vesting restricted stock units. On February 26, 2026, 1,140 shares were disposed of, and on March 1, 2026, an additional 1,079 and 8,147 shares were disposed of. After these transactions, Xie's direct holdings in Fulgent Genetics common stock total 375,313 shares, with an additional 220,816 shares held indirectly by The Hsieh Family Dynasty Trust.
